Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio

Combined organization brings broader predictive capabilities to drug discovery at scale RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions. In 2024, Chemaxon is expected to gene ...